



pharmaceuticals ltd.

Regd.&Corporate Office :  
Plot No. 19-111, Road No. 71,  
Opp. Bharatiya Vidya Bhavan Public School,  
Jubilee Hills Hyderabad - 500 096. A.P. INDIA,  
Tel : +91-40-6628 8888 Fax : +91-40-6628 8888  
CIN : L24239AP1987PL0095000  
Email : info@smspharma.com  
www.smspharma.com

By Email

June 8, 2015

**Bombay Stock Exchange Limited**  
Floor 25, P.J. Towers  
Dalal Street, Mumbai-400 001.

**Scrip Code: 532815**

Dear Sir,

**Sub: Code of Practices and Procedures for Fair Disclosure of Un-published Price Sensitive Information.**

**Ref : Our letter dated 30.05.2015.**

We enclose herewith the Code of Practices and Procedures for Fair Disclosure of Un-published Price Sensitive Information formulated pursuant to the provisions of Regulation 8 of SEBI (Prohibition of Insider Trading) Regulations, 2015 which has been approved by the Board of Directors of the Company.

Please take the same on your records.

Yours faithfully,  
For SMS Pharmaceuticals Limited



  
TVVSN MUTHY  
Vice-Chairman & Joint Managing Director

Encl: as above.

C.C. **National Stock Exchange of India Ltd.**  
Exchange Plaza, Bandra-Kurla Complex  
Bandra (E), Mumbai-400 001.

**Symbol :SMSPHARMA**

## SMS PHARMACEUTICALS LIMITED

### CODE OF PRACTICES AND PROCEDURES FOR FAIR DISCLOSURE OF UNPUBLISHED PRICE SENSITIVE INFORMATION.

(Approved by the Board of Directors of the Company on 30<sup>th</sup> May, 2015)

(FRAMED UNDER REGULATION 8 (1) OF THE SECURITIES AND EXCHANGE BOARD OF INDIA (PROHIBITION OF INSIDER TRADING) REGULATIONS, 2015).

SMS Pharmaceuticals Limited (the Company) will adhere to the following so as to ensure timely and adequate disclosure of the Price Sensitive Information with respect to it or its securities which is likely to affect price of the securities.

01. The Company will make prompt public disclosure of unpublished price sensitive information that would impact price discovery no sooner than credible and concrete information comes into being in order to make such information generally available.
02. The Company will make, uniform and universal dissemination of unpublished price sensitive information to avoid selective disclosure.
03. The Compliance Officer of the Company will be the Chief Investor relations Officer to deal with dissemination of information and disclosure of unpublished price sensitive information.
04. The Company will make prompt dissemination of unpublished price sensitive information that gets disclosed selectively, inadvertently or otherwise to make such information generally available.
05. The Company will provide, appropriate and fair response to queries on news reports and requests for verification of market rumors by regulatory authorities.
06. The Company will ensure that, information if any shared with analysts and research personnel is not unpublished price sensitive information.
07. The Company will make transcripts or records of proceedings of meeting with analysts and other investor relations conferences on the website of the Company to ensure official confirmation and documentation of disclosures made.
08. The Company will handle all unpublished price sensitive information on need to know basis.

